Basel Medical Group Ltd (BMGL) Closes Registered Direct Offering
Key Highlights
- ➤BMGL raises $7.98 million gross and approximately $7.28 million net proceeds
- ➤Offering sells 6 million units at $1.33 each, including shares and warrants
- ➤BMGL issues 6 million warrants exercisable at 110% of offering price
- ➤Zero-cash warrant exercises could add 6 million shares without additional funds
- ➤Shares outstanding rise from 1.58 million to 7.58 million post-offering
Singapore, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today closed its registered direct offering of 6,000,000 units, raising gross proceeds of US$7.98 million and estimated net proceeds of approximately US$7.28 million. The Company intends to use all of the net proceeds from this offering for general working capital purposes, mergers and acquisitions and other general corporate purposes.
As previously announced, the Company entered into a placement agency agreement with Cathay Securities, Inc., as the placement agent (the “Placement Agent”), as well as a securities purchase agreement with certain purchasers, each dated October 7, 2026, pursuant to which the Company issued and sold 6,000,000 units (the “Units”), at a public offering price of US$1.33 per Unit, each consisting of one ordinary share with no par value (each an “Ordinary Share” and collectively the “Ordinary Shares”) or one Pre-Funded Warrant in lieu thereof (defined below) of the Company, and one warrant (“Common Warrant”), each to purchase one Ordinary Share. No Pre-Funded Warrants were issued in the offering.
Get started
Create a free account to read the full story.